PgPepO is a homologue of endothelin-converting enzyme-1 (ECE-1), with which it shares 31 % identity. PgPepO was isolated from the periodontal pathogen Porphyromonas gingivalis. Recent studies have suggested a link between periodontal and cardiovascular disease, and several groups have suggested that bacterial and viral infections may contribute to the latter. P. gingivalis possesses the ability to invade, and multiply within, aortic endothelial cells and has been localized to atherosclerotic plaques. PgPepO was expressed and purified to homogeneity and we have begun detailed functional analysis, in terms of substrate preference and inhibitor specificity, in order to provide active-site comparisons with other members of the neprilysin (NEP)/ECE family. PgPepO possesses similar substrate specificity to ECE-1 and has been shown to cleave big endothelin-1 (big ET-1), big ET-2 and big ET-3, converting the substrates into their respective mature endothelin peptides. Substance P, angiotensin I, angiotensin II and neurotensin are all cleaved at multiple sites by PgPepO and the kinetics of these reactions have been compared. The potent vasoconstrictor urotensin II is not hydrolysed by PgPepO. Cleavage of bradykinin by PgPepO occurs at the Pro 7 -Phe 8 bond and is inhibited by the NEP and ECE-1 inhibitor phosphoramidon in a pH-dependent fashion (IC 50 l 10 µM at pH 7.0) but not by thiorphan, an NEP-specific inhibitor. PgPepO activity is completely inhibited by EDTA. Characterization of this enzyme is important in elucidating possible links between periodontal pathogens and cardiovascular disorders such as atherosclerosis, and provides an opportunity to gain structural information on a bacterial protein with striking similarity to human ECE-1.
INTRODUCTION
The M13 metallopeptidase family is a group of type II integral membrane proteinases each consisting of a short N-terminal cytoplasmic region and a large C-terminal extracellular catalytic domain. This group of enzymes is characterized by the first family member to be described, neutral endopeptidase-24.11 (NEP), which is also known as neprilysin. NEP has provided a valuable model on which much information on further family members has been based [1] . Endothelin-converting enzyme (ECE), as a member of the M13 family, shows substantial identity with NEP (37 % identity in rat). ECE is involved in the formation of the potent vasoconstrictor peptides the endothelins (ET-1, -2 and -3) from the biologically inactive big endothelin (big ET) species. Two ECE-like genes encoding ECE-1 [2] and ECE-2 [3] have been isolated and cloned. Owing to its involvement in the production of a potent vasoconstrictor and its wide distribution throughout the vasculature, ECE-1 has been implicated in the pathophysiology of some cardiovascular disorders [4] .
A bacterial homologue of ECE-1 named PgPepO has recently been isolated from the periodontal pathogen Porphyromonas gingivalis 381, a Gram-negative anaerobe that plays a pivotal role in acute gingivitis, the major cause of tooth loss in the adult population [5] . PgPepO was shown to possess 31 % sequence identity with ECE-1 and to efficiently cleave big ET-1 to produce ET-1 [6] . The open reading frame of PgPepO predicts a polypeptide with a putative signal sequence in the Nterminal region but with no membrane spanning domains, suggesting that it may be secreted, which could have pathological consequences. P. gingivalis 381 has also demonstrated the ability to invade and multiply within both bovine and human aortic endothelial cells in vitro [7] . Invasion of cells by this bacterial strain may influence the finely balanced equilibrium involved in ET-1 production providing a link to vascular disease. Intriguingly, recent reports have highlighted a link between cardiovascular disorders and periodontal conditions, suggesting that periodontal disease may represent a previously unrecognized risk factor for atherosclerosis and thromboembolic events [8] . The basis for this connection arises from comparable risk factors predisposing individuals to each condition. In common with periodontal disease, many pathogenic mechanisms have been proposed for atherosclerosis and are currently under investigation, but the actual mechanisms for the initiation and progression of this disease are not fully understood at present [9] . PgPepO, therefore, represents an enzyme of pathological importance and also provides an opportunity to gain more information on a member of the M13 family by study of the nature of its active site.
METHODS
PgPepO was purified to homogeneity as detailed in [6] . The substrates bradykinin, substance P, neurotensin, urotensin II, oxytocin, angiotensin I, II, and III and the inhibitors phosphoramidon (PR) and thiorphan were all obtained from Sigma (Poole, Dorset, U.K.). All other reagents were of analytical grade.
Analysis of product formation
For the detection of peptide hydrolysis, 0.1 µg PgPepO was incubated with various substrates (250 µM) in 0.1 M Tris\HCl containing 0.1 µM ZnCl # (pH 7.0) for 1 h in a total volume of 100 µl at 37 mC. Appropriate reaction mixtures contained 100 µM PR to check specificity of hydrolysis. The reactions were terminated by heating for 5 min at 100 mC.
Samples were analysed using a single quadrupole, bench top mass spectrometer coupled directly to an HPLC system. Samples were injected onto a reverse phase column (C ") , 2 mmi25 cm) that was eluted at a flow rate of 200 µl\min on a 40 min gradient of 0-50 % (v\v) acetonitrile in 0.1 % aqueous formic acid. Positive electrospray ionization was effected with a probe tip voltage of 3.5 kV, and a counter electrode voltage of 0.5 kV. Nitrogen was employed in both the nebulizing gas and the drying gas, with a nebulizing gas flow rate of 20 l\h and a drying gas flow rate of 300 l\h. The source temperature was 100 mC and the sampling cone voltage was maintained at 40 V. Data were acquired over the range m\z 50-2000 and an external calibration was applied to ensure mass accuracy. , 8i100 mm) with a UV (214 nm) detector, at a flow rate of 1.5 ml\min. Samples were eluted on a 15 min gradient of 3.6-40 % (v\v) acetonitrile in 0.08 % orthophosphoric acid. Product formation was quantified by calibration from a standard curve for both bradykinin (1-7) and substance P (1-4). Product formation was linear with respect to time and protein concentration.
Determination of kinetic parameters

RESULTS AND DISCUSSION
Determination of the characteristics of PgPepO gives an opportunity to investigate in more detail the conserved features within the active sites of the M13 family of zinc metallopeptidases. Analysis of peptide hydrolysis by PgPepO revealed cleavage of bradykinin, substance P, neurotensin, angiotensin I and angiotensin II (Figure 1) . The hydrolysis products observed correlate well with those produced by ECE-1, indicating similar substrate specificity. ECE-1, although once thought to possess very restricted substrate specificity, has since been observed to hydrolyse a variety of peptides including the ones detailed here. Bradykinin hydrolysis by PgPepO is Substrates were incubated with 0.1 µg of purified PgPepO for 1 h. Breakdown products were analysed by reverse-phase HPLC-MS. Substrate sequences are indicated by the amino acid one-letter code. The black arrows below the substrate sequences indicate PgPepO cleavage sites ; all observed cleavage events were fully inhibited by 100 µM PR. The white arrows above the sequences indicate ECE-1 cleavage sites [12] . pE represents a pyroglutamic acid residue and hydrophobic amino acids are shaded.
observed at Pro(-Phe). K m and V max values determined for this hydrolysis event are 2.1 mM and 3.3i10% nmol : min −" : mg −" respectively. PgPepO cleaves substance P at multiple bonds and the K m and V max values for this peptide are 1.0 mM and 2.0i10% nmol : min −" : mg −" respectively. The high K m values determined for each of these substrates brings into question their physiological or pathological relevance. Big ET-1 remains the most efficiently hydrolysed PgPepO substrate identified to date (K m l 12.78 nM) [6] . Urotensin II (a potent vasoconstrictor), angiotensin III and oxytocin were not hydrolysed under the conditions tested (0.1 µg PgPepO incubated at 37 mC for 1 h).
To ascertain the inhibitor profile of PgPepO the effects of PR thiorphan were investigated using bradykinin as the substrate. The fact that PgPepO was inhibited by PR (IC &! , 10 µM at pH 7.0), reinforces the enzyme's similarity to ECE-1 since PR's potency against ECE-1 is comparably in the micromolar range, while the IC &! observed against NEP is in the nanomolar range. Unexpectedly, the potent NEP inhibitor thiorphan was observed to enhance PgPepO activity to a value of 120 % over concentrations ranging from 1.0 to 50.0 µM. PR inhibition of PgPepO was seen to be pH-dependent (Figure 2) , with the IC &! falling from 10 µM at pH 7.0 to 0.55 µM at pH 5.6. This phenomenon suggests protonation of a key active site residue(s) which could, in turn, influence binding of the inhibitor. This same pH effect on PR inhibition has also been observed for ECE-1, where inhibition at pH 5.8 was 49-fold higher than at pH 7.2 [10] . PR has also been demonstrated to be 150-fold more potent against NEP at pH 6.5 than at pH 8.5 [11] .
In summary, the results presented here demonstrate a bacterial ECE-1 homologue that appears to share comparable peptide hydrolysis preferences and a similar inhibitor profile to ECE-1. Further investigation into PgPepO and its comparison with human ECE-1 will also provide information on the conservation of ECE-1 throughout evolution. This evolutionary conservation establishes the importance of ECE-1 within the vascular system.
